|
gptkbp:instanceOf
|
benzodiazepine
sedative
|
|
gptkbp:approvedBy
|
1982 (US)
|
|
gptkbp:ATCCode
|
N05CD05
|
|
gptkbp:bioavailability
|
44%
|
|
gptkbp:brand
|
gptkb:Halcion
|
|
gptkbp:CASNumber
|
28911-01-5
|
|
gptkbp:category
|
benzodiazepine
sedative
anticonvulsant
muscle relaxant
short-acting benzodiazepine
|
|
gptkbp:chemicalFormula
|
C17H12Cl2N4
|
|
gptkbp:contraindication
|
pregnancy
severe liver impairment
|
|
gptkbp:discoveredBy
|
gptkb:Upjohn
|
|
gptkbp:eliminationHalfLife
|
1.5–5.5 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
triazolam
|
|
gptkbp:interactsWith
|
gptkb:beer
CYP3A4 inhibitors
other CNS depressants
|
|
gptkbp:IUPACName
|
8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
|
|
gptkbp:legalStatus
|
gptkb:Schedule_IV_controlled_substance_(US)
|
|
gptkbp:mechanismOfAction
|
positive allosteric modulator of GABA-A receptor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
343.21 g/mol
|
|
gptkbp:origin
|
synthetic
|
|
gptkbp:pregnancyCategory
|
gptkb:X_(US)
|
|
gptkbp:prescription_status
|
prescription only
|
|
gptkbp:proteinBinding
|
89%
|
|
gptkbp:riskFactor
|
tolerance
anterograde amnesia
dependence
abuse potential
withdrawal symptoms
paradoxical reactions
complex sleep behaviors
next-day impairment
rebound insomnia
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:center
dizziness
drowsiness
impaired coordination
|
|
gptkbp:synonym
|
gptkb:Halcion
|
|
gptkbp:usedFor
|
treatment of insomnia
|
|
gptkbp:bfsParent
|
gptkb:CYP3A4
|
|
gptkbp:bfsLayer
|
5
|